We thus hypothesise that rs3827066 increases risk of CAD and AAA by disrupting a CTSA regulatory element, leading to increased expression of CTSA and elevated oxidative stress during the ECM remodelling stage of atheromatous plaque formation. This evidence concerns the gene CTSA and triple-A syndrome.